Rankia España Rankia Argentina Rankia Brasil Rankia Chile Rankia Colombia Rankia Czechia Rankia Deutschland Rankia France Rankia Indonesia Rankia Italia Rankia Magyarország Rankia México Rankia Netherlands Rankia Perú Rankia Polska Rankia Portugal Rankia Romania Rankia Türkiye Rankia United Kingdom Rankia USA
Acceder

Farmas USA

135K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
6.740 / 16.987
#53913

Re: Farmas USA

Dios las vendí cagado cuando metió el bajón, llevaba 280000 acciones , le gane pasta, le pude ganar lo que no esta escrito, pero al final sobre todo aprendí mucho, si Los fundamentales no cambian no hay que asustarse. La putada es que cuando cambian te quedas sin un chavo.

Suerte sigue pintando estupendamente, y más con la combi con el pembrolizumab.

Suerte
Oncs

#53914

Re: Farmas USA

ISCO

En realidad es una reventa de preferentes convertidas a acciones comunes contemplada en el filling anterior del 14 de octubre; nada nuevo. En principio, debería aguantar los 0,06447, que es el precio de venta estipulado y el que mantuvo ese 14 de octubre.

The securities purchase agreement entered into in the Private Placement requires us to hold a special meeting of stockholders to seek stockholder approval of an increase in the number of authorized shares of common stock under our certificate of incorporation to 720,000,000 shares and approve a reverse stock split. In connection with the Private Placement, we also entered into a registration rights agreement, as amended, with the investors pursuant to which we are obligated to file registration statements to register the resale of (i) 200% of the shares of Common Stock issuable upon conversion of the Series H Preferred Stock, and (ii) 100% of the shares of common stock issuable upon exercise of the warrants. In addition to the registration rights, the Purchasers are entitled to receive liquidated damages upon the occurrence of a number of events relating to filing, getting effective and maintaining effective registration statements covering the shares underlying the Series H Preferred Stock and the Warrants, including the failure of the Company to file a resale registration statement by no later than November 13, 2014 and the failure of the Company to have such resale registration statement declared effective by the Securities and Exchange Commission (the “SEC”) by no later than December 13, 2014, subject to certain exceptions.

Subject to certain ownership limitations with respect to the Series H-1 Preferred Stock, the Series H Preferred Stock is convertible at any time into shares of Common Stock at an initial conversion price of $0.06447 per share.


Common stock outstanding as of October 31, 2014: 224,304,073 shares(1)

Common stock to be outstanding after giving effect to the total issuance of 77,555,452 shares remaining to be sold to Purchasers under the Purchase Agreement registered hereunder:
301,859,525 shares

«Después de nada, o después de todo/ supe que todo no era más que nada.»

#53915

Re: Farmas USA

ISCO

Que alguien más letrado (o numerizado) le eche un vistado a la pagina 24 del filling. Creo que los de los fondos han tenido que quitarse acciones de encima porque se pasaban del máximo que estaban autorizados a tener.

«Después de nada, o después de todo/ supe que todo no era más que nada.»

#53916

Re: Farmas USA

Novavax to Present at the 26th Annual Piper Jaffray Healthcare Conference

http://www.novavax.com/download/releases/Novavax%20to%20Present%20at%20the%2026th%20Annual%20Piper%20Jaffray%20Healthcare%20Conference.pdf

 

Gaithersburg, MD (November 26, 2014) - Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Stanley C. Erck, President and CEO, will present at the 26th Annual Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014 at 11:00 a.m. ET in New York, NY at The New York Palace
Hotel.
 
NVAX
#53917

Re: Farmas USA

Olé esas IDRA!!!! Bien vistas....

IDRA +8,5%

#53918

Re: Farmas USA

MM200 en 3,17 y último máximo en 3,49....
RSI en diario en 80!

IDRA

#53919

Re: Farmas USA

ARQL, parece querer iniciar un tramo de subida....
Miraros el gráfico, a ver qué os parece, los que entendeis más de técnico...

AGEN y CRMD también me gusta el gráfico, y si los índices acompañan, podrían tirar para arriba.....

#53920

Re: Farmas USA

ZGNX
no levantan cabeza, en cuanto toquen 1,25 fuera